坐骨神經痛治療市場規模、佔有率和成長分析（按類型、藥物類別、通路和地區分類）—2026-2033年產業預測

2024 年全球坐骨神經痛治療市場規模為 7.6486 億美元，預計將從 2025 年的 7.9622 億美元成長到 2033 年的 10.981 億美元，預計在預測期（2026-2033 年）內將以 4.1% 的複合年成長率成長。

坐骨神經痛的盛行率不斷上升，這種疾病的特徵是疼痛從下背部沿著坐骨神經放射至腿部，這反映了治療領域的重要市場趨勢。久坐生活方式的增加、肥胖率的上升以及人口老化是導致這一趨勢的主要因素。此外，診斷技術的進步使得坐骨神經痛更容易識別，從而導致報告病例數量的增加。統計顯示，約40%的人一生中會經歷坐骨神經痛的症狀，尤其是在40至50歲的人身上。男性患者也往往比女性患者更多。這些發現凸顯了對有效治療方案的強勁需求，並強調了產業相關人員需要應對治療這種常見疾病所面臨的新挑戰。

推動全球坐骨神經痛治療市場發展的因素

全球坐骨神經痛治療市場的主要促進因素之一是久坐生活方式及其相關健康問題的日益增加。由於文書工作、不良習慣和缺乏運動等原因，越來越多的人長時間保持坐姿，導致坐骨神經痛及相關疾病的發生率不斷上升。人口老化加劇了這一趨勢，老年人罹患脊椎疾病的風險更高。因此，人們對包括藥物、物理治療和微創手術在內的有效治療方法方法的需求日益成長，這推動了坐骨神經痛治療領域的創新和投資。

全球坐骨神經痛治療市場面臨的限制因素

全球坐骨神經痛治療市場的主要限制因素之一是治療效果的差異性以及難以建立標準化的治療通訊協定。坐骨神經痛通常由多種潛在疾病引起，導致診斷和治療方法複雜多樣。這種差異性可能導致患者治療效果不一致，進而造成患者對治療不滿意，並可能使患者放棄治療。此外，先進治療方案的高成本，以及某些療法的醫療覆蓋範圍有限，進一步限制了患者獲得治療的機會。這些因素共同導致患者不願投資於可能費用高昂的坐骨神經痛治療，阻礙了市場成長。

全球坐骨神經痛治療市場趨勢

全球坐骨神經痛治療市場正經歷強勁成長，這主要得益於診斷影像技術的顯著進步，尤其是磁振造影（MRI）和電腦斷層掃描）。這些創新顯著提高了識別坐骨神經痛病因的準確性，從而能夠更快、更準確地進行診斷，並實現及時干預。重視早期診斷對於預防坐骨神經痛發展為慢性疾病至關重要，這有助於改善患者預後並降低相關殘疾的風險。隨著坐骨神經痛發病率的上升，對有效治療方法的需求也隨之增加，預計隨著醫療專業人員利用先進的成像技術來製定個性化的治療方案，從而改善治療效果，該市場將繼續擴張。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球坐骨神經痛治療市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 急性
• 慢性的
• 其他

全球坐骨神經痛治療市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 非類固醇消炎劑（NSAIDs）
• 皮質類固醇
• 抗憂鬱症
• 其他

全球坐骨神經痛治療市場規模（按分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房及網路藥房

全球坐骨神經痛治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Johnson & Johnson（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Endo Pharmaceuticals（United States）
• Stryker Corporation（United States）
• Medtronic PLC（Ireland）
• Abbott Laboratories（United States）
• Bayer AG（Germany）
• Sanofi SA（France）
• AstraZeneca PLC（United Kingdom）
• Amneal Pharmaceuticals, Inc.（United States）
• Aurobindo Pharma Limited（India）
• Sun Pharmaceutical Industries Ltd.（India）
• Sorrento Therapeutics, Inc.（United States）
• Alkem Laboratories Ltd.（India）
• Eliem Therapeutics, Inc.（United States）
• Sinfonia Biotherapeutics（United States）
• Omega Laser Systems Ltd.（United Kingdom）

結論與建議

Global Sciatica Treatment Market size was valued at USD 764.86 Million in 2024 and is poised to grow from USD 796.22 Million in 2025 to USD 1098.1 Million by 2033, growing at a CAGR of 4.1% during the forecast period (2026-2033).

The growing prevalence of sciatica, marked by pain radiating along the sciatic nerve from the lower back through the legs, reflects significant market trends in the treatment sector. Factors such as increased sedentary lifestyles, rising obesity rates, and an aging population are major contributors to this surge. Additionally, advancements in diagnostic technologies have improved sciatica identification, resulting in higher reported cases. Evidence indicates that around 40% of the population experiences sciatica symptoms during their lifetime, particularly in individuals in their 40s and 50s, with men being more frequently affected than women. These insights highlight a robust demand for effective treatment solutions and emphasize the need for industry players to address emerging challenges in managing this prevalent condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Treatment Market Segments Analysis

Global Sciatica Treatment Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Acute, Chronic and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Antidepressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies and Retail & Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Treatment Market

One of the key market drivers for the global sciatica treatment market is the increasing prevalence of sedentary lifestyles and related health issues in the population. As more individuals engage in prolonged sitting due to desk jobs, unhealthy habits, and a lack of physical activity, the incidence of sciatica and associated conditions rises. This trend is further exacerbated by the aging population, which experiences a higher likelihood of spinal issues. Consequently, there is a growing demand for effective treatments and therapies, including medications, physical rehabilitation, and minimally invasive surgeries, driving innovation and investment in the sciatica treatment sector.

Restraints in the Global Sciatica Treatment Market

One significant market restraint for the global sciatica treatment market is the variability in treatment efficacy and the challenge of creating standardized treatment protocols. Sciatica is often caused by various underlying conditions, leading to complexities in diagnosis and treatment approaches. This variability can result in inconsistent patient outcomes and dissatisfaction, which may deter individuals from seeking treatment. Additionally, the high cost of advanced treatment options, coupled with limited insurance coverage for certain therapies, can further restrict access to care. These factors collectively hinder market growth by limiting the willingness of patients to invest in potentially costly sciatica treatments.

Market Trends of the Global Sciatica Treatment Market

The Global Sciatica Treatment market is experiencing robust growth driven by significant advancements in diagnostic imaging technologies, particularly MRI and CT scans. These innovations greatly enhance the precision of identifying the underlying causes of sciatica, which facilitates quicker and more accurate diagnoses, leading to timely interventions. The emphasis on early diagnosis is pivotal in preventing the progression of sciatica into chronic conditions, thereby promoting better patient outcomes and reducing the risk of associated disabilities. With the rising incidence of sciatica fueling demand for effective treatments, the market is poised for continued expansion as healthcare professionals leverage advanced imaging to tailor interventions for improved efficacy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Sciatica Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Acute
• Chronic
• Others

Global Sciatica Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Antidepressants
• Others

Global Sciatica Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail & Online Pharmacies

Global Sciatica Treatment Market Size & CAGR (2026-2033)

• North America (Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eliem Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinfonia Biotherapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omega Laser Systems Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations